XBiotech

XBITPhase 2

Austin, United StatesFounded 2005xbiotech.com

XBiotech is dedicated to discovering and developing therapeutic antibodies sourced directly from human donors with natural immunity, a platform it calls True Human™. The company has achieved a significant milestone with the $750M sale of an IL-1α antibody and is advancing a pipeline in oncology, neurology, rheumatology, and anti-infectives. With a state-of-the-art manufacturing facility in Austin, Texas, XBiotech aims to create breakthrough therapies with improved safety profiles by leveraging the body's own immune defenses.

Market Cap

$287.9M

Founded

2005

Focus

AntibodiesBiologics

XBIT · Stock Price

USD 10.9612.29 (-52.86%)

Historical price data

AI Company Overview

Technology Platform

True Human™ antibody platform that discovers and clones therapeutic antibodies directly from the blood of human donors with natural immunity, using proprietary SHSAM™ screening and genetic cloning technologies.

Pipeline Snapshot

8 drugs in pipeline

Drug	Indication	Stage
Natrunix with MTX placebo (+folate) + Natrunix placebo with MTX (+folate)	Rheumatoid Arthritis	Phase 2
Natrunix 400 mg + Placebo + Methotrexate (MTX)	Rheumatoid Arthritis	Phase 2
Natrunix + Placebo	Axial Spondyloarthritis	Phase 2
Natrunix + Placebo	Rheumatoid Arthritis	Phase 2
XB2001 or Placebo	Pancreatic Cancer	Phase 1/2

Opportunities

Large markets in inflammatory diseases and anti-infectives where safer, naturally-derived antibodies could displace current therapies.

The proprietary manufacturing platform offers potential cost and scalability advantages.

The 2019 asset sale validates the platform's value and provides capital for pipeline advancement.

Risk Factors

Clinical failure of pipeline candidates remains a primary risk.

The company must prove its True Human™ platform offers tangible clinical benefits over established antibody technologies.

Competition in target areas like IL-1 inhibition is intense.

Competitive Landscape

Competes with large biopharma companies (e.g., AbbVie, J&J, Roche) that market antibody therapies for inflammation and cancer. Differentiates through its True Human™ discovery platform, claiming superior safety/tolerability, and its fully integrated, cost-effective in-house manufacturing capabilities.